Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease.
James AJ, Reinius LE, Verhoek M, Gomes A, Kupczyk M, Hammar U, Ono J, Ohta S, Izuhara K, Bel E, Kere J, Söderhäll C, Dahlén B, Boot RG, Dahlén SE; BIOAIR (Longitudinal Assessment of Clinical Course and Biomarkers in Severe Chronic Airway Disease) Consortium. James AJ, et al. Among authors: dahlen b, dahlen se. Am J Respir Crit Care Med. 2016 Jan 15;193(2):131-42. doi: 10.1164/rccm.201504-0760OC. Am J Respir Crit Care Med. 2016. PMID: 26372680 Free article.
Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial.
Dahlén SE, Malmström K, Nizankowska E, Dahlén B, Kuna P, Kowalski M, Lumry WR, Picado C, Stevenson DD, Bousquet J, Pauwels R, Holgate ST, Shahane A, Zhang J, Reiss TF, Szczeklik A. Dahlén SE, et al. Among authors: dahlen b. Am J Respir Crit Care Med. 2002 Jan 1;165(1):9-14. doi: 10.1164/ajrccm.165.1.2010080. Am J Respir Crit Care Med. 2002. PMID: 11779723 Clinical Trial.
Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
Gyllfors P, Bochenek G, Overholt J, Drupka D, Kumlin M, Sheller J, Nizankowska E, Isakson PC, Mejza F, Lefkowith JB, Dahlén SE, Szczeklik A, Murray JJ, Dahlén B. Gyllfors P, et al. Among authors: dahlen b, dahlen se. J Allergy Clin Immunol. 2003 May;111(5):1116-21. doi: 10.1067/mai.2003.1450. J Allergy Clin Immunol. 2003. PMID: 12743579 Clinical Trial.
Severe asthma in adults: what are the important questions?
Chanez P, Wenzel SE, Anderson GP, Anto JM, Bel EH, Boulet LP, Brightling CE, Busse WW, Castro M, Dahlen B, Dahlen SE, Fabbri LM, Holgate ST, Humbert M, Gaga M, Joos GF, Levy B, Rabe KF, Sterk PJ, Wilson SJ, Vachier I. Chanez P, et al. Among authors: dahlen b, dahlen se. J Allergy Clin Immunol. 2007 Jun;119(6):1337-48. doi: 10.1016/j.jaci.2006.11.702. Epub 2007 Apr 9. J Allergy Clin Immunol. 2007. PMID: 17416409
[TNF-blockade--new strategy in difficult-to-treat asthma].
Dahlén SE, Millinger E, Skedinger M, Zetterström O, Dahlén B. Dahlén SE, et al. Among authors: dahlen b. Lakartidningen. 2008 Jun 25-Jul 1;105(26-27):1946-8. Lakartidningen. 2008. PMID: 18681378 Swedish. No abstract available.
A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma.
Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P; T03 Asthma Investigators. Wenzel SE, et al. Among authors: dahlen se. Am J Respir Crit Care Med. 2009 Apr 1;179(7):549-58. doi: 10.1164/rccm.200809-1512OC. Epub 2009 Jan 8. Am J Respir Crit Care Med. 2009. PMID: 19136369 Clinical Trial.
353 results